Douglas J Jolly

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 7

Top Topics

Dna Methylation

Inflammatory Response

Top Venues

Cancer gene therapy

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Hiroki Niwa, Toru Nakamura, Hiroki Kushiya, Tomotaka Kuraya, Kazuho Inoko, Akihito Inagaki, Tomohiro Suzuki, Katsunori Sasaki, Takahiro Tsuchikawa, Kei Hiraoka, Toshiaki Shichinohe, Yutaka Hatanaka, Douglas J Jolly, Noriyuki Kasahara, Satoshi Hirano
Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model. Cancer gene therapy (2024)
Hiroki Niwa, Toru Nakamura, Hiroki Kushiya, Tomotaka Kuraya, Kazuho Inoko, Akihito Inagaki, Tomohiro Suzuki, Katsunori Sasaki, Takahiro Tsuchikawa, Kei Hiraoka, Toshiaki Shichinohe, Yutaka Hatanaka, Douglas J Jolly, Noriyuki Kasahara, Satoshi Hirano
Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model. Cancer gene therapy (2024)
Hiroki Kushiya, Kei Hiraoka, Tomohiro Suzuki, Kazuho Inoko, Akihito Inagaki, Hiroki Niwa, Katsunori Sasaki, Toru Nakamura, Takahiro Tsuchikawa, Toshiaki Shichinohe, Douglas J Jolly, Noriyuki Kasahara, Satoshi Hirano
Retroviral Replicating Vector Toca 511 ( Vocimagene Amiretrorepvec ) for Prodrug Activator Gene Therapy of Lung Cancer. Cancers 14 (23) (2022)
Hiroki Kushiya, Kei Hiraoka, Tomohiro Suzuki, Kazuho Inoko, Akihito Inagaki, Hiroki Niwa, Katsunori Sasaki, Toru Nakamura, Takahiro Tsuchikawa, Toshiaki Shichinohe, Douglas J Jolly, Noriyuki Kasahara, Satoshi Hirano
Retroviral Replicating Vector Toca 511 ( Vocimagene Amiretrorepvec ) for Prodrug Activator Gene Therapy of Lung Cancer. Cancers 14 (23) (2022)
Hiroki Kushiya, Kei Hiraoka, Tomohiro Suzuki, Kazuho Inoko, Akihito Inagaki, Hiroki Niwa, Katsunori Sasaki, Toru Nakamura, Takahiro Tsuchikawa, Toshiaki Shichinohe, Douglas J Jolly, Noriyuki Kasahara, Satoshi Hirano
Retroviral Replicating Vector Toca 511 ( Vocimagene Amiretrorepvec ) for Prodrug Activator Gene Therapy of Lung Cancer. Cancers 14 (23) (2022)
William P Accomando, Aliz R Rao, Daniel J Hogan, Aaron M Newman, Aki Nakao, Ash A Alizadeh, Maximillian Diehn, Oscar R Diago, Dawn Gammon, Ali Haghighi, Harry E Gruber, Douglas J Jolly, Derek Ostertag
Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (23) (2020)
Daniel J Hogan, Jay-Jiguang Zhu, Oscar R Diago, Dawn Gammon, Ali Haghighi, Guangrong Lu, Asha Das, Harry E Gruber, Douglas J Jolly, Derek Ostertag
Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients. Clinical cancer research : an official journal of the American Association for Cancer Research 24 (19) (2018)